Abstract: Levosimendan can reduce the readmission rate and mortality of patients with advanced heart failure by intermittent administration.However, so far, though there have been various methods of intermittent administration, there hasn't unified conclusion, nor has it been recommended in the manual or the authoritative guidelines.This article reviews the research on the intermittent administration of levosimendan in recent years, providing a theoretical basis for clinical rational and safe drug use.